| 000 | 01767 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250514045323.0 | ||
| 264 | 0 | _c20021205 | |
| 008 | 200212s 0 0 eng d | ||
| 022 | _a0006-4971 | ||
| 024 | 7 |
_a10.1182/blood-2002-03-0990 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPreudhomme, Claude | |
| 245 | 0 | 0 |
_aFavorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). _h[electronic resource] |
| 260 |
_bBlood _cOct 2002 |
||
| 300 |
_a2717-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBone Marrow _xpathology |
| 650 | 0 | 4 |
_aCCAAT-Enhancer-Binding Protein-alpha _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSequence Deletion |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited Kingdom |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aSagot, Christophe | |
| 700 | 1 | _aBoissel, Nicolas | |
| 700 | 1 | _aCayuela, Jean-Michel | |
| 700 | 1 | _aTigaud, Isabelle | |
| 700 | 1 | _ade Botton, Stéphane | |
| 700 | 1 | _aThomas, Xavier | |
| 700 | 1 | _aRaffoux, Emmanuel | |
| 700 | 1 | _aLamandin, Charlotte | |
| 700 | 1 | _aCastaigne, Sylvie | |
| 700 | 1 | _aFenaux, Pierre | |
| 700 | 1 | _aDombret, Hervé | |
| 773 | 0 |
_tBlood _gvol. 100 _gno. 8 _gp. 2717-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2002-03-0990 _zAvailable from publisher's website |
| 999 |
_c12164055 _d12164055 |
||